Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas.

[1]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[2]  J. Huse,et al.  Evaluation of Histone 3 Lysine 27 Trimethylation (H3K27me3) and Enhancer of Zest 2 (EZH2) in Pediatric Glial and Glioneuronal Tumors Shows Decreased H3K27me3 in H3F3A K27M Mutant Glioblastomas , 2013, Brain pathology.

[3]  Xuan Sun,et al.  Protocadherin-7 induces bone metastasis of breast cancer. , 2013, Biochemical and biophysical research communications.

[4]  E. Zwarthoff,et al.  Hypermethylation of the polycomb group target gene PCDH7 in bladder tumors from patients of all ages. , 2013, The Journal of urology.

[5]  Mahlon D. Johnson,et al.  Transcriptional differences between normal and glioma-derived glial progenitor cells identify a core set of dysregulated genes. , 2013, Cell reports.

[6]  B. Garcia,et al.  Inhibition of PRC2 Activity by a Gain-of-Function H3 Mutation Found in Pediatric Glioblastoma , 2013, Science.

[7]  Sabine Mueller,et al.  The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression. , 2013, Genes & development.

[8]  Robert E. Kingston,et al.  Occupying chromatin: Polycomb mechanisms for getting to genomic targets, stopping transcriptional traffic, and staying put. , 2013, Molecular cell.

[9]  David T. W. Jones,et al.  Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas , 2013, Acta Neuropathologica.

[10]  Wendy A Bickmore,et al.  Redistribution of H3K27me3 upon DNA hypomethylation results in de-repression of Polycomb target genes , 2013, Genome Biology.

[11]  A. P. Graves,et al.  Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2. , 2012, ACS medicinal chemistry letters.

[12]  David T. W. Jones,et al.  Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. , 2012, Cancer cell.

[13]  B. Langmead,et al.  BSmooth: from whole genome bisulfite sequencing reads to differentially methylated regions , 2012, Genome Biology.

[14]  David T. W. Jones,et al.  K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas , 2012, Acta Neuropathologica.

[15]  Michael C. Rusch,et al.  Abstract 4869: Whole genome sequence analysis of MLL rearranged infant acute lymphoblastic leukemias reveals remarkably few somatic mutations: A Report From the St Jude Children's Research Hospital - Washington University Pediatric Cancer Genome Project , 2012 .

[16]  E. Greer,et al.  Histone methylation: a dynamic mark in health, disease and inheritance , 2012, Nature Reviews Genetics.

[17]  David T. W. Jones,et al.  Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma , 2012, Nature.

[18]  Li Ding,et al.  Somatic Histone H3 Alterations in Paediatric Diffuse Intrinsic Pontine Gliomas and Non-Brainstem Glioblastomas , 2012, Nature Genetics.

[19]  J. Uhm.  IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype , 2012 .

[20]  B. Christensen,et al.  Polycomb group genes are targets of aberrant DNA methylation in renal cell carcinoma , 2011, Epigenetics.

[21]  R. Stewart,et al.  Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells , 2011, Nature.

[22]  D. Reinberg,et al.  The Polycomb complex PRC2 and its mark in life , 2011, Nature.

[23]  Jean Mosser,et al.  A 4-Gene Signature Associated with Clinical Outcome in High-Grade Gliomas , 2011, Clinical Cancer Research.

[24]  C. Hawkins,et al.  Whole-genome profiling of pediatric diffuse intrinsic pontine gliomas highlights platelet-derived growth factor receptor alpha and poly (ADP-ribose) polymerase as potential therapeutic targets. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Peter W. Laird,et al.  DNA Methylation Profiles of Ovarian Epithelial Carcinoma Tumors and Cell Lines , 2010, PloS one.

[26]  J. Licht,et al.  Deregulation of H3K27 methylation in cancer , 2010, Nature Genetics.

[27]  S. Gabriel,et al.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.

[28]  Gerald L. Arthur,et al.  DNA hypermethylation accompanied by transcriptional repression in follicular lymphoma , 2009, Genes, chromosomes & cancer.

[29]  H. Cedar,et al.  Linking DNA methylation and histone modification: patterns and paradigms , 2009, Nature Reviews Genetics.

[30]  Gangning Liang,et al.  Frequent switching of Polycomb repressive marks and DNA hypermethylation in the PC3 prostate cancer cell line , 2008, Proceedings of the National Academy of Sciences.

[31]  Gordon B Mills,et al.  Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers , 2008, Molecular carcinogenesis.

[32]  D. Gold,et al.  Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation , 2008, Nature Genetics.

[33]  Xiaozhong Peng,et al.  Cooperation between EZH2, NSPc1-mediated histone H2A ubiquitination and Dnmt1 in HOX gene silencing , 2008, Nucleic acids research.

[34]  B. Scheithauer,et al.  The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.

[35]  M. Fraga,et al.  The Polycomb group protein EZH2 directly controls DNA methylation , 2007, Nature.

[36]  Zohar Yakhini,et al.  Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer , 2007, Nature Genetics.

[37]  P. Laird,et al.  Epigenetic stem cell signature in cancer , 2007, Nature Genetics.

[38]  D. Louis.  WHO classification of tumours of the central nervous system , 2007 .

[39]  M. Weller,et al.  TGF-β and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells , 2006 .

[40]  Annie P. Moseman,et al.  Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells. , 2006, Cancer research.

[41]  James A. Cuff,et al.  A Bivalent Chromatin Structure Marks Key Developmental Genes in Embryonic Stem Cells , 2006, Cell.

[42]  Megan F. Cole,et al.  Control of Developmental Regulators by Polycomb in Human Embryonic Stem Cells , 2006, Cell.

[43]  M. Weller,et al.  TGF-b and metalloproteinases differentially suppress NKG 2 D ligand surface expression on malignant glioma cells , 2006 .